NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 40 min 43 sec ago

Notice of Change to Science Supported by PAR-17-316 "Biomedical Technology Research Resource (P41)"

Wed, 2019-04-03 13:31
Notice NOT-GM-19-033 from the NIH Guide for Grants and Contracts

Notice of Change to Science Supported by PAR-17-045 "Focused Technology Research and Development (R01)"

Wed, 2019-04-03 13:22
Notice NOT-GM-19-034 from the NIH Guide for Grants and Contracts

Notice of Change to Science Supported by PAR-17-046 "Exploratory Research for Technology Development (R21)"

Wed, 2019-04-03 13:15
Notice NOT-GM-19-035 from the NIH Guide for Grants and Contracts

Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed)

Wed, 2019-04-03 12:28
Funding Opportunity PA-19-237 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.

NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)

Wed, 2019-04-03 11:56
Funding Opportunity RFA-RM-19-005 from the NIH Guide for Grants and Contracts. The NIH Directors Pioneer Award supports individual scientists of exceptional creativity who propose highly innovative and potentially transformative research towards the ultimate goal of enhancing human health. Individuals from diverse backgrounds are encouraged to apply. Applications in all topics, including, but not limited to, the behavioral, social, biomedical, applied, and formal sciences, relevant to the broad mission of NIH are welcome and may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigators research program or elsewhere. The NIH Directors Pioneer Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Data Analysis, Informatics and Resource Center (U24 Clinical Trial Not Allowed)

Wed, 2019-04-03 02:45
Funding Opportunity RFA-DA-20-003 from the NIH Guide for Grants and Contracts. NIDA and the following NIH Institutes and Centers (ICs), NIAAA, NICHD, NIMH, NIMHD, NINDS, OBSSR, and NCI intend to publish a Collaborative Research on Addiction at NIH (CRAN) funding opportunity announcement to solicit applications for a Data Analysis, Informatics, and Resource center to oversee and manage the standardization of data collection procedures, provide technical support, ensure quality control, perform integrative data analysis, and coordinate data storage and data sharing activities for a nationwide, multisite, multi-modal, longitudinal cohort study that prospectively examines brain and behavioral development from late childhood (approximately age 9-10) through adolescence into early adulthood. Current primary awardees will be eligible to apply and this new award period will be extended to 7 years in duration.

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Linked Research Project Sites (Collaborative U01 Clinical Trial Not Allowed)

Wed, 2019-04-03 02:45
Funding Opportunity RFA-DA-20-002 from the NIH Guide for Grants and Contracts. NIDA and the following NIH Institutes and Centers (ICs), NIAAA, NICHD, NIMH, NIMHD, NINDS, OBSSR, and NCI intend to publish a Collaborative Research on Addiction at NIH (CRAN) funding opportunity announcement to solicit applications for research project sites in service of a nationwide, multisite, multi-modal, longitudinal cohort study to prospectively examine brain and behavioral development from late childhood (approximately age 9-10) through adolescence into early adulthood. Current primary awardees will be eligible to apply and this new award period will be extended to 7 years in duration.

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Coordinating Center (U24 Clinical Trial Not Allowed)

Wed, 2019-04-03 02:45
Funding Opportunity RFA-DA-20-004 from the NIH Guide for Grants and Contracts. NIDA and the following NIH Institutes and Centers (ICs), NIAAA, NICHD, NIMH, NIMHD, NINDS, OBSSR, and NCI intend to publish a limited competition Collaborative Research on Addiction at NIH (CRAN) funding opportunity announcement to solicit applications for a Coordinating Center in service of a nationwide, multisite, multi-modal, longitudinal cohort study to prospectively examine brain and behavioral development from late childhood (approximately age 9-10) through adolescence into early adulthood. Current primary awardees will be eligible to apply and this new award period will be extended to 7 years in duration.

Request for Proposals (RFP) Notice: Preparation and Distribution of Research Drug Products

Tue, 2019-04-02 13:51
Notice NOT-DA-19-062 from the NIH Guide for Grants and Contracts

Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required)

Tue, 2019-04-02 13:38
Funding Opportunity PAR-19-236 from the NIH Guide for Grants and Contracts. Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based Coordinated Specialty Care (CSC) for early psychosis, and effective engagement in CSC services are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks research project grant applications that test practical, reproducible strategies for substantially reducing DUP among persons with FEP in the U.S. by eliminating bottlenecks or closing gaps in the pathway to CSC services.

Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required)

Tue, 2019-04-02 13:38
Funding Opportunity PAR-19-235 from the NIH Guide for Grants and Contracts. Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based Coordinated Specialty Care (CSC) for early psychosis, and effective engagement in CSC services are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks planning research project grant applications that (1) identify a baseline rate of DUP in community or institutional settings; (2) map referral pathways to CSC care, (3) identify bottlenecks and gaps in the pathway to CSC care, and (4) develop and pilot test feasible strategies for substantially reducing DUP among persons with FEP.

Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project (U01 Clinical Trial Not Allowed)

Tue, 2019-04-02 13:07
Funding Opportunity PAR-19-234 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study.

Notice of Special Interest: High-Priority Research Topic for PAR-19-070

Tue, 2019-04-02 12:06
Notice NOT-AG-19-012 from the NIH Guide for Grants and Contracts

Notice of Special Interest: Availability of Administrative Supplements for NIMH Grants to Expand Suicide Research

Tue, 2019-04-02 03:01
Notice NOT-MH-19-026 from the NIH Guide for Grants and Contracts

Targeted Prevention for Tickborne Diseases (R01 Clinical Trial Not Allowed)

Tue, 2019-04-02 02:23
Funding Opportunity RFA-AI-19-037 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage the development of vaccines and other approaches for the prevention of Lyme disease and/or other tick-borne diseases.

Pages